{"entity":{"id":"medpace","kind":"company","name":"Medpace","aka":[],"tldr":"Medpace, of Cincinnati, is a mid-sized full-service contract research organisation whose physician-led model keeps medical oversight, the imaging core laboratory and central laboratories in-house, a package that biotechnology companies buy for oncology programmes. Whether in-house imaging and laboratories give cleaner oncology endpoints than outsourcing is unproven.","summary":"Medpace, based in Cincinnati and listed as MEDP, is a mid-sized full-service contract research organisation whose clients are mostly biotechnology companies, including for oncology programmes. Its physician-led model keeps medical oversight in-house, as are its imaging core laboratory and central laboratories. OnCo links it to contract research organisations and to imaging core labs and central review. Whether keeping imaging and laboratory work in-house gives cleaner oncology endpoints than outsourcing them is the argument behind its model and the open question. The CRO technology page carries the wider picture.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Medpace","links":[{"label":"Official website","url":"https://www.medpace.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["contract-research-organisations","imaging-core-labs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07432633","nct07702292","nct05986851","nct07189871","nct07197580","nct04329728","nct06777433"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cincinnati, OH","country":"US","companyType":"cro-services","website":"https://www.medpace.com","ticker":"MEDP","investors":[],"funding":[]},"route":"/companies/medpace/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"}],"technology":[{"id":"contract-research-organisations","kind":"technology","name":"Contract research organisations (CROs)","route":"/technologies/contract-research-organisations/"},{"id":"imaging-core-labs","kind":"technology","name":"Imaging core labs and central review","route":"/technologies/imaging-core-labs/"}],"trial":[{"id":"nct07432633","kind":"trial","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07432633/"},{"id":"nct07702292","kind":"trial","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07702292/"},{"id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/"},{"id":"nct05986851","kind":"trial","name":"Azeliragon in MGMT Unmethylated Glioblastoma","route":"/trials/nct05986851/"},{"id":"nct06777433","kind":"trial","name":"Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases","route":"/trials/nct06777433/"},{"id":"nct07197580","kind":"trial","name":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","route":"/trials/nct07197580/"},{"id":"nct04329728","kind":"trial","name":"The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies","route":"/trials/nct04329728/"}]}}